Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Q4 FY24 Earnings Presentation
10 slides from Curvebeam Ai's earnings presentation, Aug 7, 2024
Slide 1: Presentation for Quarterly 4C Conference Call
ASX ANNOUNCEMENT ASX: CVB 7 August 2024 Presentation for Quarterly 4C Conference Call CurveBeam AI Limited (ASX:CVB) (the Company) herewith provides the presentation for today’s Quarterly 4C Conference Call at 12:00pm (midday). Release approved by the Board. About CurveBeam AI Limited CurveBeam AI L
Slide 2: Quarterly 4C Conference Call
QUARTERLY 4C CONFERENCE CALL August 7th 2024
Slide 3: Disclaimer
DISCLAIMER Introduction THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, Forward looking statements DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY The information given in this presentation is given for illustrative purposes only
Slide 4: 4C Summary of Key Activities
In Market 4C SUMMARY OF KEY ACTIVITIES • CurveBeam AI received purchase orders (POs) for 10 devices in Q4, up from 6 in Q3. • The 10 POs represent A$4.9m of revenue carried into FY25. • The Company submitted its 510(k) application for the enhanced HiRise™ in Q4 FY24 TM (FDA clearance announced after
Slide 5: 4C Summary of Key Activities
4C SUMMARY OF KEY ACTIVITIES In Market Device Purchase Orders Q1 Q2 Q3 Q4 US 2 2 3 5 Rest of World 1 2 3 5 Total 3 4 6 10 Device Purchase Orders by Region 12 10 8 6 TM 4 2 0 Q1 Q2 Q3 Q4 Discontinued US Rest of World 10 7 6 4 4 3 3 3 3 3 0 0 FY24 Q1 FY24 Q2 FY24 Q3 FY 24 Q4 Total orde rs HiRise Lin e
Slide 6: Update on expected FY24 Revenue and Net Loss
Update on expected FY24 Revenue and Net Loss • Full year revenue for FY24 is expected to be A$6.5m (unaudited), down from A$8.1m in FY23, or A$11.5m pro-forma for FY23. • The POs received in 4Q FY24 represent A$4.9m which will be recognised in FY25 as devices are shipped and installed. • FY25 begins
Slide 7: Enhanced HiRise Project
ENHANCED HIRISE™ PROJECT • CurveBeam AI has completed the development of the Enhanced HiRise™ platform and is now FDA 510(k) cleared. CE and TGA targeted next. • Enhanced HiRise™ WBCT scans, with higher energy X-Ray source, allows key anatomical landmarks to be identified in larger patients – these
Slide 8: BMD HiRise Module Progress
BMD HIRISE™ MODULE PROGRESS Today MDCT • BMD module is targeting a key Software as a Service (SaaS) annuity stream for sales & profit growth off knee & hip CT scans in the US market. • In the US, there are approx.1.6 million hip and knee total joint replacements, versus approx. 350,000 ankle-related
Slide 9: In Closing
IN CLOSING • Enhanced HiRise™ progress • Cadaver models scans on Enhanced HiRise™ were successfully processed for specific custom cut guides for a major robotic aided surgical system. • Enhanced HiRise FDA clearance was achieved in July 2024. • Post FDA, the Company has arranged US reference sites t
Slide 10: Definitions
DEFINITIONS CurveBeam AI’s key metrics are defined and interpreted as follows: • Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time. • Receipts from customers – any cash consideration rec